| E.1 Medical condition or disease under investigation |
| E.1.1 | Medical condition(s) being investigated |
| Chronic Phase Chronic Myeloid Leukemia |
|
| E.1.1.1 | Medical condition in easily understood language |
| Chronic Phase Chronic Myeloid Leukemia |
|
| E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
| MedDRA Classification |
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 20.0 |
| E.1.2 | Level | LLT |
| E.1.2 | Classification code | 10054352 |
| E.1.2 | Term | Chronic phase chronic myeloid leukemia |
| E.1.2 | System Organ Class | 100000004864 |
|
| E.1.3 | Condition being studied is a rare disease | Yes |
| E.2 Objective of the trial |
| E.2.1 | Main objective of the trial |
To characterize the efficacy of ponatinib administered in 3 starting doses
(45 mg, 30 mg, and 15 mg daily) in patients with CP-CML who are
resistant to prior TKI therapy or have T315I mutation, as measured by
≤ 1% BCR-ABL1IS at 12 months. |
|
| E.2.2 | Secondary objectives of the trial |
•To characterize the rate of major molecular response (MMR) at 12 and
24 months and rate of major cytogenetic response (MCyR) by 12 months
•To evaluate duration of MMR
•To characterize the rates of AOEs, VTEs, AEs, and serious AEs (SAEs)
•To evaluate safety differences among the 3 starting dose cohorts,
particularly for AOEs and VTEs
•To collect sparse PK samples to contribute to population PK and
exposure-response analyses of safety and efficacy
•To characterize the rates of cytogenetic responses and molecular
responses; durability will be assessed by evaluating ≤ 1% BCR-ABL1IS
response and major molecular response (MMR) at and by 6, 12, 18, and
24 months
•To characterize the rate of discontinuation, dose reductions, and
interruptions
•To characterize the rates of hematologic responses
•To evaluate time to response, duration of response, and survival
outcomes |
|
| E.2.3 | Trial contains a sub-study | No |
| E.3 | Principal inclusion criteria |
1. Have CP-CML and have received at least two prior TKI therapies and
have demonstrated resistance to treatment
OR
Have documented history of presence of T315I mutation after receiving
any number of prior TKI.
a. The diagnosis of CML will be made using standard hematopathologic
and cytogenetic criteria; CP-CML will be defined by all of the following:
i. < 15% blasts in bone marrow
ii. < 30% blasts plus promyelocytes in bone marrow
iii. < 20% basophils in peripheral blood
iv. ≥ 100 × 109/L platelets (≥ 100,000/mm3)
v. No evidence of extramedullary disease except hepatosplenomegaly
vi. No prior diagnosis of AP- or BP-CML
b. Cytogenetic assessment at screening must demonstrate the BCR-ABL1
fusion by presence of the t(9;22) Philadelphia chromosome
i. Variant translocations are only allowed provided they meet inclusion
criterion 1d
c. Resistance to prior TKI therapy is defined as follows (patients must
meet at least 1 criterion):
i. Three months after the initiation of prior TKI therapy: No cytogenetic
response (> 95% Ph+) or failure to achieve CHR or new mutation
ii. Six months after the initiation of prior TKI therapy: BCR-ABL1IS
>10% and/or Ph+ >65% or new mutation
iii. Twelve months after the initiation of prior TKI therapy: BCR-ABL1IS
>10% and/or Ph+ >35% or new mutation.
iv. At any time after the initiation of prior TKI therapy, the development
of a new BCR-ABL1 kinase domain mutation(s).
v. At any time after the initiation of prior TKI therapy, the development
of new clonal evolution
vi. At any time after the initiation of prior TKI therapy, the loss of CHR,
or CCyR, or the confirmed loss of MMR in 2 consecutive tests, one of
which has a BCR-ABL1IS transcript level of ≥1% or new mutation
d. > 1% of BCR-ABL1IS as shown by real-time polymerase chain reaction
2. Age ≥ 18 years old.
3. Have an Eastern Cooperative Oncology Group (ECOG) performance
status of 0, 1, or 2.
4. Have adequate renal function as defined by the following criterion:
a. Serum creatinine ≤ 1.5 × upper limit of normal (ULN) for institution
b. Estimated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault
formula)
5. Have adequate hepatic function as defined by the following criteria:
a. Total serum bilirubin ≤ 1.5 × ULN, unless due to Gilbert's syndrome
b. Alanine aminotransferase (ALT) ≤ 2.5 × ULN, or ≤ 5 × ULN if leukemic
infiltration of the liver is present
c. Aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN if
leukemic infiltration of the liver is present
6. Have normal pancreatic status as defined by the following criterion:
a. Serum lipase and amylase ≤ 1.5 × ULN
7. Have normal QT interval corrected (Frederica) (QTcF) interval on
screening electrocardiogram (ECG) evaluation, defined as QTcF of ≤ 450
ms in males or ≤ 470 ms in females.
8. Have a negative pregnancy test documented prior to enrollment (for
females of childbearing potential).
9. Agree to use a highly effective form of contraception with sexual
partners from randomization through at least 4 months after the end of
treatment (for female and male patients who are fertile).
10. Provide written informed consent.
11. Be willing and able to comply with scheduled visits and study
procedures.
12. Have recovered from toxicities related to prior anticancer therapy to
NCI CTCAE v 4.0 grade ≤1. |
|
| E.4 | Principal exclusion criteria |
1. Have used any approved TKIs or investigational agents within 2
weeks or 6 half-lives of the agent, whichever is longer, prior to receiving
study drug.
2. Received interferon, cytarabine or immunotherapy within 14 days; or
any other cytotoxic chemotherapy, radiotherapy, or investigational
therapy within 28 days prior to receiving the first dose of ponatinib, or
have not recovered (> grade 1 by the National Cancer Institute Common
Terminology Criteria for Adverse Events [NCI CTCAE], v4.0) from AEs
(except alopecia) due to agents previously administered.
3. Have undergone autologous or allogeneic stem cell transplant (SCT) <
60 days prior to receiving the first dose of ponatinib; have any evidence
of ongoing graft versus-host disease (GVHD) or GVHD requiring
immunosuppressive therapy.
4. Are being considered for hematopoietic SCT (HSCT) within 6-12
months of enrollment (note: ponatinib is not to be used as a bridge to
HSCT in this trial).
5. Are taking medications with a known risk of Torsades de Pointes.
6. Have previously been treated with ponatinib.
7. Have active central nervous system (CNS) disease as evidenced by
cytology or pathology; in the absence of clinical CNS disease, lumbar
puncture is not required. History itself of CNS involvement is not
exclusionary if CNS has been cleared with a documented negative
lumbar puncture.
8. Have clinically significant, uncontrolled, or active cardiovascular
disease, specifically including, but not restricted to:
a. Any history of myocardial infarction (MI), unstable angina,
cerebrovascular accident, or transient ischemic attack (TIA)
b. Any history of peripheral vascular infarction, including visceral
infarction
c. Any revascularization procedure, including the placement of a stent
d. Congestive heart failure (CHF) (New York Heart Association [NYHA]
class III or IV) within 6 months prior to enrollment, or left ventricular
ejection fraction (LVEF) less than lower limit of normal, per local
institutional standards, within 6 months prior to enrollment
e. History of clinically significant (as determined by the treating
physician) atrial arrhythmia or any history of ventricular arrhythmia
f. Venous thromboembolism, including deep venous thrombosis or
pulmonary embolism, within 6 months prior to enrollment
9. Have uncontrolled hypertension (i.e., >150 and >90 for SBP and DBP,
respectively). Patients with hypertension should be under treatment at
study entry to ensure blood pressure control. Those requiring 3 or more
antihypertensive medications should be discussed with the medical
monitor.
10. Have poorly controlled diabetes defined as HbA1c values of > 7.5%.
Patients with preexisting, well-controlled, diabetes are not excluded.
11. Have a significant bleeding disorder unrelated to CML.
12. Have a history of alcohol abuse.
13. Have a history of either acute pancreatitis within 1 year of study
enrollment or of chronic pancreatitis.
14. Have malabsorption syndrome or other gastrointestinal illness that
could affect oral absorption of study drug.
15. Have a history of another malignancy, other than cervical cancer in
situ or basal cell or squamous cell carcinoma of the skin; the exception is
if patients have been disease-free for at least 5 years and are deemed by
the investigator to be at low risk for recurrence of that malignancy.
16. Are pregnant or lactating.
17. Have undergone major surgery (with the exception of minor surgical
procedures, such as catheter placement or BM biopsy) within 14 days
prior to the first dose of ponatinib.
18. Have an active infection which requires intravenous antibiotics.
19. Have a known history of human immunodeficiency virus infection;
testing is not required in the absence of prior documentation or known
history.
20. Have any condition or illness that, in the opinion of the investigator,
would compromise patient safety or interfere with the evaluation of the
drug.
21. Have hypersensitivity to the ponatinib active substance or to any of
its inactive ingredients listed in Section 14.7.1 of the protocol. |
|
| E.5 End points |
| E.5.1 | Primary end point(s) |
|
| E.5.1.1 | Timepoint(s) of evaluation of this end point |
| At 12 months for each starting dose cohort. |
|
| E.5.2 | Secondary end point(s) |
•Molecular response rates: MMR at 12 and 24 months
•Cytogenetic response rates: MCyR by 12 months
•Duration of MMR
•Safety
a.Rate of AOEs and VTEs in each dose cohort
b.Rate of AEs in each dose cohort
c.Rate of SAEs in each dose cohort
•Cytogenetic response rates: CCyR at 12 months
•Molecular response rates: MR4, and MR4.5 by and at 3-month intervals
and MR1 (≤ 10% BCR-ABL1IS) at 3 months
•Hematologic response rate: Complete hematologic response (CHR) at 3
months
•Tolerability:
a.Rate of discontinuation due to AEs in each dose cohort
b.Dose reductions due to AE in each dose cohort
c.Dose interruptions in each dose cohort
•Duration of response:
a.Rate of ≤1% BCR-ABL1IS by 12 months and at and by 6, 18, and 24
months
b.MMR at and by 6 and 18 months; and by 12 and 24 months
•Duration of response in responders
•Time to response
•Rate of progression to accelerated phase (AP-) or blast phase (BP-)
CML
•PFS
•OS |
|
| E.5.2.1 | Timepoint(s) of evaluation of this end point |
| At each visit and the final analysis will be done at the end of the study. |
|
| E.6 and E.7 Scope of the trial |
| E.6 | Scope of the trial |
| E.6.1 | Diagnosis | No |
| E.6.2 | Prophylaxis | No |
| E.6.3 | Therapy | Yes |
| E.6.4 | Safety | Yes |
| E.6.5 | Efficacy | Yes |
| E.6.6 | Pharmacokinetic | Yes |
| E.6.7 | Pharmacodynamic | No |
| E.6.8 | Bioequivalence | No |
| E.6.9 | Dose response | Yes |
| E.6.10 | Pharmacogenetic | No |
| E.6.11 | Pharmacogenomic | No |
| E.6.12 | Pharmacoeconomic | No |
| E.6.13 | Others | No |
| E.7 | Trial type and phase |
| E.7.1 | Human pharmacology (Phase I) | No |
| E.7.1.1 | First administration to humans | No |
| E.7.1.2 | Bioequivalence study | No |
| E.7.1.3 | Other | No |
| E.7.1.3.1 | Other trial type description | |
| E.7.2 | Therapeutic exploratory (Phase II) | Yes |
| E.7.3 | Therapeutic confirmatory (Phase III) | No |
| E.7.4 | Therapeutic use (Phase IV) | No |
| E.8 Design of the trial |
| E.8.1 | Controlled | Yes |
| E.8.1.1 | Randomised | Yes |
| E.8.1.2 | Open | Yes |
| E.8.1.3 | Single blind | No |
| E.8.1.4 | Double blind | No |
| E.8.1.5 | Parallel group | Yes |
| E.8.1.6 | Cross over | No |
| E.8.1.7 | Other | No |
| E.8.2 | Comparator of controlled trial |
| E.8.2.1 | Other medicinal product(s) | No |
| E.8.2.2 | Placebo | No |
| E.8.2.3 | Other | Yes |
| E.8.2.3.1 | Comparator description |
| This is a controlled study of ponatinib at three different starting doses. |
|
| E.8.2.4 | Number of treatment arms in the trial | 3 |
| E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
| E.8.4 | The trial involves multiple sites in the Member State concerned | No |
| E.8.5 | The trial involves multiple Member States | Yes |
| E.8.5.1 | Number of sites anticipated in the EEA | 49 |
| E.8.6 Trial involving sites outside the EEA |
| E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
| E.8.6.2 | Trial being conducted completely outside of the EEA | No |
| E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
| Argentina |
| Australia |
| Belgium |
| Canada |
| Chile |
| Czech Republic |
| Denmark |
| Finland |
| France |
| Germany |
| Hong Kong |
| Italy |
| Japan |
| Korea, Republic of |
| Netherlands |
| Norway |
| Poland |
| Portugal |
| Russian Federation |
| Singapore |
| Spain |
| Sweden |
| Taiwan |
| United Kingdom |
| United States |
|
| E.8.7 | Trial has a data monitoring committee | Yes |
| E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
| E.8.9 Initial estimate of the duration of the trial |
| E.8.9.1 | In the Member State concerned years | 6 |
| E.8.9.1 | In the Member State concerned months | 1 |
| E.8.9.1 | In the Member State concerned days | |
| E.8.9.2 | In all countries concerned by the trial years | 6 |
| E.8.9.2 | In all countries concerned by the trial months | 1 |
Print
